Arvinas 향후 성장

Future 기준 점검 0/6

Arvinas 의 수익과 수익은 각각 연간 17.6% 및 25.5% 감소할 것으로 예상됩니다. EPS는 연간 20.5% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -37% 로 예상됩니다.

핵심 정보

-25.5%

이익 성장률

-20.54%

EPS 성장률

Pharmaceuticals 이익 성장	14.4%
매출 성장률	-17.6%
향후 자기자본이익률	-36.96%
애널리스트 커버리지	Good
마지막 업데이트	07 Dec 2025

최근 향후 성장 업데이트

Recent updates

Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating

Nov 24

Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified

Sep 09

We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate

Jun 01

Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry

May 01

Phase III And PROTAC Data Will Advance Pipeline Despite Hurdles

Mar 24 Successful trials and partnerships in oncology could support Arvinas' transition to commercial operations, driving growth and revenue potential.

Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects

Mar 14

Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%

Mar 12

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Jul 12

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Jun 27

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

May 05

이익 및 매출 성장 예측

NasdaqGS:ARVN - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	99	-244	-186	-166	12
12/31/2026	101	-220	-208	-168	15
12/31/2025	290	-49	-33	N/A	16
9/30/2025	312	-58	-329	-327	N/A
6/30/2025	373	-73	-399	-396	N/A
3/31/2025	427	-47	-253	-251	N/A
12/31/2024	263	-199	-261	-259	N/A
9/30/2024	161	-309	-260	-258	N/A
6/30/2024	93	-323	-217	-215	N/A
3/31/2024	71	-355	-356	-354	N/A
12/31/2023	79	-367	-351	-348	N/A
9/30/2023	159	-295	-340	-336	N/A
6/30/2023	158	-298	-323	-318	N/A
3/31/2023	137	-301	-313	-308	N/A
12/31/2022	131	-282	-280	-273	N/A
9/30/2022	127	-253	-246	-238	N/A
6/30/2022	103	-233	503	510	N/A
3/31/2022	75	-213	536	541	N/A
12/31/2021	54	-191	555	559	N/A
9/30/2021	23	-180	562	566	N/A
6/30/2021	21	-164	-142	-138	N/A
3/31/2021	21	-139	-118	-112	N/A
12/31/2020	26	-119	-96	-90	N/A
9/30/2020	24	-99	-83	-77	N/A
6/30/2020	47	-86	-59	-53	N/A
3/31/2020	45	-78	-52	-45	N/A
12/31/2019	43	-70	-47	-41	N/A
9/30/2019	42	-65	-42	-37	N/A
6/30/2019	15	-173	N/A	-50	N/A
3/31/2019	14	-179	N/A	-48	N/A
12/31/2018	14	-240	N/A	-16	N/A
9/30/2018	13	-233	N/A	24	N/A
6/30/2018	12	-114	N/A	28	N/A
3/31/2018	10	-98	N/A	31	N/A
12/31/2017	8	-29	N/A	5	N/A
12/31/2016	7	-12	N/A	-19	N/A

애널리스트 향후 성장 전망

수입 대 저축률: ARVN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ARVN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ARVN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ARVN 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -17.6%).

고성장 매출: ARVN 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -17.6%).

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ARVN는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/26 18:19
종가	2025/12/24 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Arvinas, Inc.는 28명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Peter Lawson	Barclays
Etzer Darout	Barclays
Tazeen Ahmad	BofA Global Research

Arvinas 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Price target decreased by 32% to US$12.44

Price target decreased by 7.9% to US$34.24

Price target decreased by 8.9% to US$39.47

Price target decreased by 18% to US$50.05

Consensus EPS estimates upgraded to US$3.69 loss

Consensus revenue estimates increase by 20%

Recent updates

Price target decreased by 32% to US$12.44

Arvinas, Inc. Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab At the 2025 American Society of Hematology Annual Meeting and Exposition

Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating

Arvinas, Inc. to Report Q3, 2025 Results on Nov 05, 2025

Arvinas, Inc. Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-Mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer

Arvinas, Inc. Announces New Patient-Reported Outcomes (PRO) Data from the Phase 3 Veritac-2 Clinical Trial Evaluating Vepdegestrant

Arvinas, Inc. Presents Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Arvinas, Inc. Approves Reduction in Workforce of Approximately 15% Across Roles in Functional Areas of the Company Primarily Related to Vepdegestrant Commercialization

Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Arvinas, Inc. to Report Q2, 2025 Results on Aug 06, 2025

Arvinas Announces Retirement of John Houston, Ph.D., Chairperson as President

Insufficient new directors

Arvinas, Inc. Announces John Young Decides to Resign from its Board of Directors and Compensation Committee, Effective June 30, 2025

Logos Global Management LP Issues a Letter to the Board of Arvinas, Inc.

Arvinas, Inc. Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Arvinas and Pfizer Announce Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate

Price target decreased by 7.9% to US$34.24

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry

Arvinas, Inc., Annual General Meeting, Jun 25, 2025

Arvinas, Inc. to Report Q1, 2025 Results on May 01, 2025

Arvinas Announces Results from the Veritac-2 Trial Selected as Late-Breaking Oral Presentation At the 2025 American Society of Clinical Oncology Annual Meeting

Price target decreased by 8.9% to US$39.47

Arvinas, Inc. Presents First-In-Human Data for Investigational Oral Protac ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

Insider recently sold US$74k worth of stock

Phase III And PROTAC Data Will Advance Pipeline Despite Hurdles

Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects

Price target decreased by 18% to US$50.05

Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%

New major risk - Share price stability

Arvinas, Inc. and Pfizer Inc. Announce Positive Topline Results from Phase 3 Veritac-2 Clinical Trial

Chairperson recently sold US$524k worth of stock

Consensus EPS estimates upgraded to US$3.69 loss

Full year 2024 earnings: EPS exceeds analyst expectations

Arvinas, Inc. to Report Q4, 2024 Results on Feb 11, 2025

Arvinas, Inc. Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant

Arvinas' Vepdegestrant: Why The Data May Not Hold Up

Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans

Arvinas and Pfizer Announces Initial Phase 1B Data from the Tactive-U Sub-Study of Vepdegestrant in Combination with Abemaciclib At 2024 San Antonio Breast Cancer Symposium

Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)

Consensus revenue estimates increase by 20%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause

Consensus revenue estimates increase by 23%

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Arvinas, Inc.(NasdaqGS:ARVN) dropped from Russell Small Cap Comp Value Index

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Arvinas, Inc. Appoints Andrew Saik as Treasurer

Arvinas, Inc. Announces Presentations for Two of Its PROTAC Investigational Programs Targeting BCL6 and LRRK2

Arvinas Announces Promotions of Ian Taylor to President of Research and Development and Angela Cacace to Chief Scientific Officer

Arvinas, Inc. Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE)

Consensus revenue estimates increase by 17%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Arvinas, Inc. Appoints Randy Teel as Chief Business Officer

Arvinas, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$5.13 loss

Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee

Arvinas: Behind The Huge Rally

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$5.76 loss

Arvinas, Inc. announced that it has received $349.999871 million in funding from a group of investors

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. Announces Treasurer Changes, Effective February 29, 2024